Member Info for roses

No don’t sell, just understand what you are invested in. Research will get you far in life.

Uncanny, do you not remember how long each dose escalation extension lasted ?

Unfortunately, this looks like it will need to last much longer.

Bermudashorts thank you for your 15.22pm post.

I must admit whilst I am fact orientated, I quite often lack the skills to convey it in a way that the the regulars on here will see the point of the post rather than assuming there must be a motive behind it.

You seem to have hit the nail on the head, and I will try and post the facts in a more ‘diplomatic way’ in an attempt to keep the more hard core holders a touch calmer.

Marmited, it's in the last paragraph, They have just catagoricaly stated that there is insufficient data to proceed to the next phase. and will need to reassess dosage levels and dosage interval times. this sort of trial will take at least 12-18 months to plan and execute with at least a 6 month evaluation so probably 2 years or more.

"We now have to decide which is the most effective dosing strategy for the compound so that it has maximal impact upon the disease progression , WE CAN EITHER GO HIGH AMOUNTS INFREQUENTLY GIVEN , LOW AMOUNTS FREQUENTLY GIVEN OR THERE IS A THIRD ALTERNATIVE WHERE WE TREAT VERY HEAVILY FOR A SHORT WHILE AND THEN GIVE A RESPITE FROM TREATMENT FOR A PERIOD OF TIME "

ok, as promised here's is the quotes from the interview.
apologies for any typos as it was done quickly for marmited.

"in a non oncological setting the current trial is classed as a phase 1"

" we have discovered from the trial that the pre-clinical evidence as to the amount of compound that could be accumulated in the tissue of the test animals have in fact been found to be much higher in humans when they are treated in the same way , now this put a limitation on the AMOUNT AND FREQUENCY of the compound that we could give subjects, which hasn't so far proved to be a problem from a therapeutical level , but WE WERE OCCASIONALLY OVERSHOOTING OUR REGULATED AMOUNTS WITH INDIVIDUALS., to no ill effect whatsoever, HOWEVER THIS NEEDED TO BE REGULARISED AND REGULATED AND THAT IN ITSELF WAS THE SUBSTANTIAL AMMENDMENT TO THE TRIAL..

Other than that, there were changes in procedures and protocols where experience had shown that frequency of administrations were not the best or most practical way of going about things.

'interviewer '
"whats the next stage of things" ?

We now have to decide which is the most effective dosing strategy for the compound so that it has maximal impact upon the disease progression , WE CAN EITHER GO HIGH AMOUNTS INFREQUENTLY GIVEN , LOW AMOUNTS FREQUENTLY GIVEN OR THERE IS A THIRD ALTERNATIVE WHERE WE TREAT VERY HEAVILY FOR A SHORT WHILE AND THEN GIVE A RESPITE FROM TREATMENT FOR A PERIOD OF TIME "

Does this really sound like a company that knows what it's next step is ????

Ok marmited, calm down.

I’m not at home at the minute, I just log on while I’m travelling. I’ll need 20 mins to listen to the recording and write down what they say, then type it on here.

Don’t get your panties in a bunch.

Will do when I get a few spare minutes.

Have you listened to the interview. It will answer all your questions and back up what I'm saying.

Marmited - there is no need to decide for yourself!

Just listen to the last brr interview from last week and they tell you exactly where it is.

Borgie, no you are not wrong and you heard correctly.

We now need to re-trial with different doses and different dosing intervals (as stated in the interview) if you go by Vals previous timeline it will take between 1 and two years.

As expected, and no doubt will be extended again.

Interesting post from ADVFN

NXC4 Jul '19 - 20:46 - 5472 of 5473
0 1 0
Thanks Bermudashorts - I have known the company for 14 years and had some ill-fated interactions when I was Chairman at Physiomics ( a story for another day) The main actors have not changed which tells its own story. I am not invested but the cluster**** of the recent financing intrigued me sufficiently to consider whether there was a trading opportunity. I am not a trader by nature and therefore will probably sit on the sidelines and watch out of idle curiosity. I have recently taken a position in Circasia due to the Woodford situation which will work its way out in due course.

Dracula, I have answered it at least 20 times, why do you want me to keep repeating it ?

Borgie, it was unfortunate that 201 had so many restrictions on recruitment and it would be good news if 301 didn't have the same restrictions but I don't recall the company confirming that?

Strange how they have dropped any reference to 201’s efficacy in today’s RNS.
They used to say it was showing signs of preliminary efficacy.

They now just say it is safe and well tolerated.

Apologies valju, my figures were incorrect, it was much more.

In fact the consolidation was done at 3.7 billion shares.

“The Company's issued share capital currently consists of approximately 3.7 billion Existing Ordinary Shares. This number of shares in issue is considerably higher than the majority of companies on AIM, and the Board believes this affects investor perception of the Company. The Directors believe that the Capital Reorganisation should improve the marketability of ordinary shares to a range of investors, including institutional investors.”

Well that worked then didn’t it, lol.

The last consolidation was 3.2 billion and they changed the share price to 22p with a market cap of around 2 million.
So the rise To 79p took it to around 7 million market cap.

Valju, I’m sure the directors more than recouped their initial investment when they floated the company onto aim

‘In your previous post mentioning me’

Valju, I think you are getting confused, I didn’t say anything about George or even mention him previous to post mentioning me.

teamhanz -why wait until it's too late to do anything ?